Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Immunologic Features of Primary Enteric-Type Thymic Adenocarcinomas: A Rare Variant of a Rare Cancer.

JTO clinical and research reports·2026
Same author

Long-Term Outcomes of Surgery for Thymic Epithelial Tumors With Pleural Metastases.

JTO clinical and research reports·2026
Same author

Cancer Prevention Clinical Trials: Advances and Challenges.

Cancers·2026
Same author

Corrigendum to 'Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact' [Journal of Thoracic Oncology Volume 21 Issue 1 (2026) 41-76].

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026
Same author

Immune aberrations in thymic epithelial tumors.

Mediastinum (Hong Kong, China)·2026

Related Experiment Video

Updated: Jun 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Targeted therapy for advanced thymic tumors.

Arun Rajan1, Giuseppe Giaccone

  • 1Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|September 23, 2010
PubMed
Summary

Targeted therapies show limited success in thymic malignancies due to insufficient patient selection and small study sizes. Further research into tumor biology is crucial for advancing treatment strategies.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 8, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Targeted therapies are being explored for thymic malignancies.
  • Limited clinical trial data exists for these treatments.

Purpose of the Study:

  • To review the current evidence for targeted and biologic therapies in thymic malignancies.
  • To identify challenges and future directions for treatment development.

Main Methods:

  • Literature review of existing studies on targeted therapies for thymic malignancies.
  • Analysis of reported clinical trial data, case reports, and case series.

Main Results:

  • Few targeted therapies have been evaluated in Phase II trials.
  • Evidence primarily consists of case reports and small series.
  • No significant activity observed with current agents, likely due to poor patient selection and small sample sizes.

Conclusions:

  • Current targeted therapies have shown limited efficacy in thymic malignancies.
  • Improved patient selection and larger studies are needed.
  • A deeper understanding of thymic tumor biology is essential for future therapeutic advancements.